scispace - formally typeset
S

Sara Darakhshan

Researcher at Razi University

Publications -  10
Citations -  635

Sara Darakhshan is an academic researcher from Razi University. The author has contributed to research in topics: Tranilast & Tamoxifen. The author has an hindex of 5, co-authored 9 publications receiving 469 citations. Previous affiliations of Sara Darakhshan include Kermanshah University of Medical Sciences.

Papers
More filters
Journal ArticleDOI

Thymoquinone and its therapeutic potentials.

TL;DR: Report on and analyze numerous properties of the active ingredient of N. sativa seeds, TQ, in the context of its therapeutic potentials for a wide range of illnesses and summarize the drug's possible mechanisms of action.
Journal ArticleDOI

Tranilast: a review of its therapeutic applications

TL;DR: The findings presented in this review demonstrate the potential of tranilast for the control of a vast array of pathological situations, furthermore, it is a prescribed drug without severe side effects.
Journal ArticleDOI

Tranilast enhances the anti-tumor effects of tamoxifen on human breast cancer cells in vitro

TL;DR: Findings indicate that tranilast, by synergistic effect, enhances the activity of tamoxifen and the TGF-β pathway is a target for this combination therapy, therefore, it is proposed that this combined treatment may be suitable selection in prevention of breast cancer.
Journal ArticleDOI

Synergistic Effects of Tamoxifen and Tranilast on VEGF and MMP-9 Regulation in Cultured Human Breast Cancer Cells

TL;DR: In this paper, the effects of tamoxifen and tranilast drugs singly or in combination on proliferation of breast cancer cells and also to evaluate VEGF and MMP-9 expression and VEGf secretion levels were examined by real-time RT-PCR and ELISA assay.
Journal ArticleDOI

The effects of tamoxifen in combination with tranilast on cxcl12- cxcr4 axis and invasion in breast cancer cell lines

TL;DR: Tranilast increases antimetastatic effect of tamoxifen and tranilast drugs as a single or in combination on invasion by two in-vitro invasion assays, and supports the importance of the CXCR4/CXCL12 interaction in breast cancer metastasis, and suggests that CX CR4 and CXCL 12 are critical targets for tamoxIFen andtranilasts in combination or alone.